The use of modeling in the economic evaluation of vaccines.
As a consequence of the increased role of pharmacoeconomics in policy-making, economic evaluations are performed at more and more early stages in the development of a therapeutic. This implies the development of models to assess the future impact of an intervention and to account for the level of uncertainty in the associated parameters. This also applies for economic evaluations of vaccines, where not only progression of disease and associated costs are important, but the transmission of the causing agent in the target population also has to be modelled. In this review, we provide an overview of the models that have been used in recent publications on the pharmacoeconomics of vaccines and go deeper into some of the methodological issues associated with the use of models in the economic evaluation of vaccines.
Bos
Jasper M
JM
GUIDE, Dept. of Social Pharmacy, University Groningen, Antonius Deusinghlaan 1, 9713 AV, Groningen, The Netherlands. J.Bos@farm.rug.nl
Alphen
Loek van
Lv
Postma
Maarten J
MJ